Related Experiment Video
Updated: Jun 22, 2026
Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
Published on: December 15, 2010
Experimental study of the preparation of targeted microbubble contrast agents carrying urokinase and RGDS
Yuming Mu1, Ling Li, Guligena Ayoufu
1Department of Echocardiography, First Affiliated Hospital, Xinjiang Medical University, Urumqi 830000, PR China. yuming.mu@hotmail.com
Purpose:
To explore the feasibility and the best combined proportion of the preparation of targeted and thrombolytic contrast agents carrying urokinase (UK) and Arg-Gly-Asp-Ser (RGDS), and to study its effect of thrombolysis in vitro.
Methods:
Urokinase and RGDS were combined to the surface of SonoVue by direct conjugation method. According to the different ratio of urokinase and RGDS when mixed, they were divided into three groups whose urokinase/RGDS were 1:1, 2:1 and 1:2, respectively. To measure the binding rate of microbubbles and urokinase as well as RGDS by flow cytometry. To detect the effect of thrombolysis by thrombolytic experiment in vitro. To detect the targeting effects by experiment in vivo.
Results:
The results of flow cytometry detection showed that the binding rates of urokinase and RGDS of three groups were, respectively, 73.4+/-11.0% and 67.1+/-10.9%, 8.8+/-7.2% and 7.8+/-6.9%, 49.7+/-21.3% and 45.9+/-21.7% after standing for 2h. In vitro thrombolysis experiment indicated that the urokinase had activity in the prepared contrast agent which the binding rates of urokinase and RGDS were the highest. And it was injected intravenous, the contrast agent aggregated on the surface of the thrombus of the rabbit femoral arterial. The thrombus emitted fluorescence.
Conclusions:
The binding rate of the targeted contrast agent prepared by 1:1 of urokinase/RGDS was the highest. It had thrombolysis ability in vitro, and it had thrombo-targeting effect in vivo.
